View Older Stories View More Recent Stories

Jun 2, 2016 07:35AM ARIAD Completes the Sale of Its European Operations and Out-License of European Rights to Iclusig®
Jun 1, 2016 07:35AM ARIAD to Present at the Jefferies 2016 Global Healthcare Conference
May 31, 2016 07:41AM ARIAD Pharma (ARIA) Commences AP32788 Phase 1/2 in NSCLC
May 31, 2016 07:35AM ARIAD Announces Initiation of Phase 1/2 Clinical Trial of AP32788, an Investigational Oral Inhibitor of EGFR and HER2, in Patients with Non-Small Cell Lung Cancer
May 24, 2016 09:26AM ARIAD Pharma (ARIA) Taps Bristol-Myers Squibb's Herron as Chief Commercial Officer
May 24, 2016 09:25AM ARIAD Announces Appointment of Jennifer L. Herron as Chief Commercial Officer
May 19, 2016 07:36AM ARIAD Pharma (ARIA) Updates on Iclusig Pricing and Reimbursement in France; Will Record Q2 Net Product Revenue
May 19, 2016 07:35AM ARIAD Announces Pricing and Reimbursement for Iclusig in France
May 18, 2016 05:11PM ARIAD Pharma (ARIA) Announces Data Presentations at ASCO
May 18, 2016 05:08PM ARIAD Announces Data Presentations at the 2016 ASCO Annual Meeting
May 10, 2016 07:35AM ARIAD Reports First Quarter 2016 Financial Results and Progress on Strategic Review
May 9, 2016 07:03AM Incyte (INCY) to Acquire ARIAD's (ARIA) European Operations; Will in-License Iclusig
May 9, 2016 07:00AM Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe
Apr 26, 2016 07:35AM ARIAD to Webcast Conference Call on First Quarter 2016 Financial Results
Apr 19, 2016 07:37AM ARIAD Pharma (ARIA) Announces Positive Results from AP32788 in Certain NSCLC
Apr 19, 2016 07:35AM ARIAD Announces Results of Preclinical Studies on AP32788 at the Annual Meeting of the American Association for Cancer Research
Apr 15, 2016 07:44AM ARIAD Pharma (ARIA) Announces Updated Brigatinib Phase 1/2 Data in ALK+ NSCLC; Includes Safety, PK Results
Apr 15, 2016 07:35AM ARIAD Presents Updated Phase 1/2 Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer
Apr 11, 2016 07:35AM ARIAD Pharma (ARIA) Begins Brigatinib Phase 3 in ALK-Positive NSCLC
Apr 11, 2016 07:35AM ARIAD Announces Initiation of Randomized, First-Line Phase 3 Trial of Brigatinib in Treatment of ALK-Positive Non-Small Cell Lung Cancer
Mar 29, 2016 12:52PM ARIAD Pharma (ARIA) to Cut HQ Workforce by ~25%
Mar 29, 2016 12:51PM ARIAD Announces Reduction in Workforce as Part of Ongoing Company-Wide Strategic Review
Mar 22, 2016 07:35AM ARIAD Reports Inducement Grant to New Chief Financial Officer
Mar 11, 2016 07:36AM ARIAD Pharma (ARIA) Taps Pharmacyclics' Soni as CFO
Mar 11, 2016 07:35AM ARIAD Announces Appointment of Manmeet S. Soni as Chief Financial Officer
Feb 29, 2016 07:35AM ARIAD to Present at Upcoming Investor Conferences
Feb 23, 2016 07:35AM ARIAD Reports 2015 Financial Results, Provides 2016 Product Revenue Guidance and Outlines Company Progress
Feb 10, 2016 07:35AM ARIAD to Present at the RBC Capital Markets Healthcare Conference
Feb 2, 2016 07:35AM ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2015 Financial Results
Feb 1, 2016 07:36AM ARIAD Pharma (ARIA) Cleared by U.S. FDA to Commence Development of AP32788
Feb 1, 2016 07:35AM ARIAD Announces FDA Clearance to Begin Clinical Development of AP32788
Jan 15, 2016 07:35AM ARIAD Reports Inducement Grant to New Chief Executive Officer
Jan 11, 2016 07:38AM ARIAD Pharma (ARIA) Terminates Section 382 Rights Agreement
Jan 11, 2016 07:35AM ARIAD Announces Termination of Shareholder Rights Plan
Jan 11, 2016 06:42AM ARIAD Pharma (ARIA) Elects New Board Chair
Jan 10, 2016 06:30PM ARIAD Announces Election of Alex Denner as Chairman of the Board of Directors
Jan 8, 2016 07:36AM ARIAD Pharma (ARIA) Announces Submission of Iclusig NDA in Japan as CML, Ph+ALL Treatment
Jan 8, 2016 07:35AM ARIAD and Otsuka Submit New Drug Application in Japan for Ponatinib
Dec 18, 2015 07:36AM ARIAD Pharma (ARIA) Names New CEO
Dec 18, 2015 07:35AM ARIAD Names Paris Panayiotopoulos as Its President and Chief Executive Officer
Dec 11, 2015 07:36AM ARIAD Pharma (ARIA) Still in Talks with French Regulator on Iclusig Pricing; Trims Revenue Outlook
Dec 11, 2015 07:35AM ARIAD Announces Pricing and Reimbursement Negotiations for Iclusig in France to Continue into 2016
Dec 7, 2015 07:37AM ARIAD Pharma (ARIA) Announces Initiation of Iclusig Phase 3 in Chronic CML in the CP
Dec 7, 2015 07:35AM ARIAD Announces Initiation of OPTIC-2L Randomized Phase 3 Trial of ponatinib vs. nilotinib in Second-Line Patients with Chronic-Phase Chronic Myeloid Leukemia
Nov 5, 2015 04:05PM ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting
Nov 3, 2015 07:35AM ARIAD Reports Third Quarter 2015 Financial Results and Progress on Strategic Objectives
Oct 27, 2015 07:35AM ARIAD to Webcast Conference Call on Third Quarter 2015 Financial Results
Sep 15, 2015 07:35AM ARIAD Announces Full Enrollment in Phase 2 ALTA Trial of Brigatinib
Aug 31, 2015 09:25AM Pre-Open Stock Movers 08/31: (VTL) (MDCO) (TWTR) Higher; (ARIA) (AUY) (UTX) Lower (more...)
Aug 10, 2015 07:35AM ARIAD Announces First Patient Treated in Phase 2 Dose-Ranging Optic Trial of Iclusig (Ponatinib)
View More Recent Stories View Older Stories